Bart N.M. van Berckel

Author

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

B N M van Berckel, B van Berckel, B. Berckel, B. N. M. van Berckel, B.N. van Berckel, B.N.M van Berckel, B.N.M. Van Berckel, B.N.M. van Berckel, Bart N M van Berckel, Bart N Van Berckel

501

Publications

19.5K

Citations

H-Index

144

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam Neuroscience Amsterdam University Medical Centers Vrije Universiteit Amsterdam University College London

About

Bart N.M. van Berckel is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in neuroscience, medicine, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	40	3.9K
2	Health Sciences	13	13	722
3	Engineering	11	11	569
4	Education	3	3	213
5	Natural Sciences	2	2	113

Bart N.M. van Berckel

212

Publications

15.6K

Citations

H-Index

Page 1

	Year	Citations
Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study Bart N.M. van Berckel, Matthijs G. Bossong, Ronald Boellaard, Biological Psychiatry Neuroimaging BiomarkersPsychiatryMedicineRecent-onset SchizophreniaSchizophrenia	2008	578
The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features Rik Ossenkoppele, Yolande A.L. Pijnenburg, David C. Perry, Brain	2015	533
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort Wiesje M. van der Flier, Yolande A.L. Pijnenburg, Niels D. Prins, Journal of Alzheimer s Disease	2014	412
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment Maja Binnewijzend, Menno M. Schoonheim, Ernesto Sanz‐Arigita, Neurobiology of Aging Neuroimaging BiomarkersAlzheimer's DiseaseBrain FunctionMedicineDementia	2011	390
Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum Matthijs G. Bossong, Bart N.M. van Berckel, Ronald Boellaard, Neuropsychopharmacology Cannabis UseHuman StriatumMolecular NeurosciencePsychoactive DrugNeuropharmacology	2008	384
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Stephanie J. B. Vos, Frans R.J. Verhey, Lutz Frölich, Brain	2015	384
Plasma Amyloid as Prescreener for the Earliest <scp>A</scp>lzheimer Pathological Changes Inge M.W. Verberk, Rosalinde E.R. Slot, Sander C.J. Verfaillie, Annals of Neurology	2018	309
Blood–brain barrier P-glycoprotein function in Alzheimer's disease Daniëlle M. E. van Assema, Mark Lubberink, Martin Bauer, Brain	2011	304
Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity Maja Binnewijzend, Joost P.A. Kuijer, Marije R. Benedictus, Radiology	2012	263
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology Inge M.W. Verberk, Elisabeth H. Thijssen, Jannet Koelewijn, Alzheimer s Research & Therapy	2020	251

Page 1